or Try an Advanced Search...

    Hepatitis C Virus Infection Stocks List

    Symbol Grade Name % Change
    BMY F Bristol-Myers Squibb Company -0.78
    IONS F Ionis Pharmaceuticals, Inc. -1.37
    RGLS D Regulus Therapeutics Inc. -0.48
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Hepatitis C Hepatitis C Virus Biopharmaceutical Diabetes Dystrophy Genetics Hepatitis B Hepatitis B Virus Lipodystrophy Treatment Of Diabetes Acromegaly Alcohol Alnylam Pharmaceuticals Alport Syndrome Amyloid Amyloidosis Angioedema Antisense RNA Apatorsen Atherosclerosis

    Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C Virus Infection stocks.

    Symbol Grade Name Weight
    FTXH C First Trust Nasdaq Pharmaceuticals ETF 6.83
    MEDX D Horizon Kinetics Medical ETF 4.71
    ARKG D ARK Genomic Revolution Multi-Sector ETF 4.43
    WBIY B WBI Power Factor High Dividend ETF 4.39
    IHE C iShares U.S. Pharmaceutical ETF 3.93
    View all Hepatitis C Virus Infection ETFs...
    Compare ETFs
    Compare ARKG to WBIY Compare FTXH to ARKG Compare FTXH to MEDX

        Hepatitis C Virus Infection Stocks Recent News

        Date Stock Title
        May 13 BMY Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)
        May 13 BMY One stock is dragging down the S&P 500's earnings growth
        May 13 BMY BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
        May 13 BMY Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
        May 13 BMY These Stocks Are Moving the Most Today: GameStop, AMC, Arm, Squarespace, Tesla, Intel, Apple, Incyte, and More
        May 13 BMY BMS Opdivo and Yervoy combo misses primary endpoint in Phase III NSCLC trial
        May 12 BMY Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip
        May 11 BMY Is Bristol Myers' Dividend in Danger?
        May 10 BMY Bristol Myers' Opdivo fails in Phase 3 lung cancer study
        May 10 BMY Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
        May 10 BMY Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
        May 10 BMY 2 Beaten-Down Stocks to Buy and Hold for 10 Years
        May 9 RGLS Regulus Therapeutics GAAP EPS of -$0.29
        May 9 RGLS Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
        May 9 IONS The Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
        May 9 BMY Q1 2024 Editas Medicine Inc Earnings Call
        May 8 IONS Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript
        May 8 IONS Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
        May 8 IONS Ionis Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
        May 8 BMY Bristol-Myers Squibb Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Hepatitis C Hepatitis C Virus Biopharmaceutical Diabetes Dystrophy Genetics Hepatitis B Hepatitis B Virus Lipodystrophy Treatment Of Diabetes Acromegaly Alcohol Alnylam Pharmaceuticals Alport Syndrome Amyloid Amyloidosis Angioedema Antisense RNA Apatorsen Atherosclerosis
        Hepatitis C Virus Infection

        Hepatitis C virus (HCV) infection is a contagious liver disease caused by the hepatitis C virus. It is spread through contact with the blood of an infected person. Symptoms of HCV infection can range from mild to severe and may include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored stools, joint pain, and jaundice. In some cases, HCV infection can lead to serious liver problems, including cirrhosis and liver cancer. Treatment for HCV infection typically involves a combination of antiviral medications.

        Browse All Tags